The GG 257 pill is a prescription medication containing Alprazolam 0.5 mg. Manufactured by Sandoz Pharmaceuticals, it is a generic form of the brand-name medication Xanax.
Alprazolam belongs to the benzodiazepine class of central nervous system (CNS) depressants. In the United States, it is categorized as a Schedule IV controlled substance due to its potential for physical dependence, misuse, and addiction.
Physical Identification
While some pill queries casually refer to “blue” or “white” variants across different strengths (such as the 1 mg blue GG 258 or 2 mg white GG 249), the official physical characteristics of the GG 257 tablet are distinct:
Characteristic Details
- Active Ingredient Alprazolam (0.5 mg)
- Imprint “GG 257” on one side, scored on the other
- Color Orange / Peach
- Shape Oval
- Score Line Scored (allowing it to be split into two 0.25 mg halves)
- Manufacturer Sandoz Pharmaceuticals
- Safety Warning: Counterfeit pills pressed to imitate prescription benzodiazepines are common on the illicit market. Never consume a tablet unless it was dispensed directly by a licensed, legitimate pharmacy.
Mechanism of Action
Alprazolam acts centrally by enhancing the activity of gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the human brain.
- GABA-A Receptor Binding: Alprazolam selectively binds to the benzodiazepine binding site on the GABA-A receptor complex in the central nervous system.
- Chloride Influx Acceleration: This binding modifies the receptor structure, increasing GABA affinity and allowing a higher frequency of chloride channel openings.
- Neuronal Hyperpolarization: The resulting influx of negatively charged chloride ions hyperpolarizes the postsynaptic neuron, lowering its overall excitability and reducing hyperactive brain signals associated with anxiety and panic.
This mechanism produces rapid anxiolytic (anti-anxiety), sedative, muscle-relaxant, and anticonvulsant effects.
Indications & Dosage
Alprazolam is FDA-approved for the acute treatment of Generalized Anxiety Disorder (GAD) and Panic Disorder (with or without agoraphobia) in adults.
Adult Dosing Guidelines (Immediate-Release)
- Generalized Anxiety Disorder (GAD):
- Starting Dose: Typically 0.25 mg to 0.5 mg administered orally 3 times daily.
- Titration: May be increased every 3 to 4 days based on clinical response.
- Maximum Limit: 4 mg per day (divided across doses).
- Panic Disorder:
- Starting Dose: 0.5 mg administered 3 times daily.
- Titration: Can be increased by no more than 1 mg per day every 3 to 4 days.
- Maintenance: Mean effective doses typically range between 3 mg and 6 mg per day, though some patients with severe panic disorder may require up to 10 mg per day.
Special Dosage Adjustments
- Geriatric Patients & Debilitated Adults: The recommended starting dosage is 0.25 mg 2 to 3 times daily to lower the risk of excessive sedation or impaired motor coordination.
- Hepatic Impairment: Therapy should start at 0.25 mg 2 to 3 times daily due to altered drug metabolism and clearance.
Side Effects
Common Side Effects
Side effects usually occur at the onset of therapy or during dose escalation and often decrease as tolerance to sedation develops:
- Drowsiness, somnolence, and fatigue
- Lightheadedness, dizziness, or unsteadiness
- Impaired coordination or difficulty with balance (ataxia)
- Memory problems or cognitive slowing
- Dry mouth or slurred speech
Serious Side Effects
Seek emergency medical treatment immediately if you experience:
- Severe Respiratory Depression: Dangerously slow, shallow, or irregular breathing.
- Paradoxical Reactions: Unexpected excitement, agitation, aggression, severe irritability, or hallucinations.
- Depression & Suicidal Ideation: Sudden mood changes, severe depression, or self-harm thoughts.
- Severe Allergic Reactions (Anaphylaxis): Hives, difficulty swallowing, or swelling of the face, lips, tongue, or throat.
Boxed Warnings & Key Precautions
FDA Black Box Warnings
- Concomitant Use with Opioids or Alcohol: Taking benzodiazepines alongside opioids or alcohol can cause profound sedation, severe respiratory depression, coma, and death.
- Abuse, Misuse, and Addiction: Use of alprazolam exposes users to risks of misuse, addiction, and fatal overdose.
- Physical Dependence and Withdrawal: Prolonged use causes physical dependence. Abruptly stopping or rapidly tapering alprazolam can cause severe, life-threatening withdrawal symptoms, including status epilepticus (uncontrolled seizures), tremors, delirium, and severe rebound anxiety.
Contraindications
Do not use the GG 257 tablet if you have:
- Known hypersensitivity or allergy to alprazolam or other benzodiazepines.
- Acute narrow-angle glaucoma.
- Concurrent treatment with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole), which block alprazolam elimination.
Pregnancy & Lactation Precautions
- Pregnancy: Alprazolam crosses the placenta and can cause fetal toxicity, congenital abnormalities, neonatal hypotonia (“floppy infant syndrome”), hypothermia, and neonatal withdrawal symptoms if used late in pregnancy.
- Lactation: Excreted in breast milk; may cause excessive sedation and lethargy in nursing infants.
Drug Interactions
Class / Medication Interaction Risk Clinical Precaution
- Opioids & CNS Depressants Synergistic respiratory depression, profound coma, and death. Avoid co-administration unless under strict medical supervision.
- Strong CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole) Inhibits hepatic clearance, raising alprazolam blood concentrations to toxic levels. | Strictly contraindicated.
- Moderate CYP3A4 Inhibitors (e.g., fluconazole, erythromycin, cimetidine) Decreases alprazolam clearance, increasing sedative side effects. | Requires dosage reduction and clinical monitoring.
- Grapefruit Juice Inhibits intestinal CYP3A4, increasing oral absorption and overall exposure. Avoid consuming grapefruit or its juice during therapy.